Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Annovis Bio is a late-stage clinical drug platform company that develops novel disease-modifying therapies for neurodegenerative diseases.</li><li>The company recently initiated a Phase 3 study in its lead small molecule candidate Buntanetap, which targets early-stage Alzheimer’s.</li><li>Annovis completed a Phase 3 study of Buntanetap for Parkinson’s and is expected to meet with the FDA in 2Q25 to determine the path forward for the program.</li></ul>

Annovis Bio is a late-stage clinical drug platform company that develops novel disease-modifying therapies for neurodegenerative diseases.The company recently initiated a Phase 3 study in its lead small molecule candidate Buntanetap, which targets early-stage Alzheimer’s.Annovis completed a Phase 3 study of Buntanetap for Parkinson’s and is expected to meet with the FDA in 2Q25 to determine the path forward for the program.

ANVS: CEO on Taking Treatments of Neurodegenerative Diseases to the Next Level

United States

Annovis Bio, Inc. operates as a biotechnology company. The Company develops drugs for alzheimer's and parkinson's disease, including the orphan indication dementia and alzheimer's in down syndrome. Annovis Bio serves customers in the State of Pennsylvania.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00